An Open-Label Phase 1 Study in Healthy Adult Male Subjects to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6 Following Single-Dose Oral Administration
Latest Information Update: 23 May 2024
At a glance
- Drugs HU 6 (Primary)
- Indications Heart failure; Hypertriglyceridaemia; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Rivus Pharmaceuticals
Most Recent Events
- 20 May 2024 Status changed from recruiting to completed.
- 16 Apr 2024 Status changed from not yet recruiting to recruiting.
- 27 Mar 2024 New trial record